Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers
https://www.facingourrisk.org/research-clinical-trials/study/232/testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT04491942 (https://clinicaltrials.gov/show/NCT04491942)
Treatment study for people with advanced cancers
Study Contact Information:
For additional information, please contact:
Principal Investigator: Dr. Mamta Parikh
City of Hope Comprehensive Cancer Center
916-734-3089
About the Study
This study is how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.
This study is no longer enrolling people.
What the Study Involves
There will be two groups in this study. All participants will receive the study drug elimusertib. People will be assigned to a group based on their cancer type.
Group 1: Ovarian, endometrial, triple-negative breast, urothelial, gastric, biliary tract, lung, head and neck
- Participants will receive the chemotherapy drug cisplatin intravenously over 1-2 hours on day 1 and 8.
- Participants will take elimusertib orally once daily on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles as long as the cancer doesn’t get worse and there are no unacceptable side effects.
Group 2: Urothelial cancers only
- Participants will receive cisplatin intravenously over 1-2 hours on day 1 and 8, gemcitabine intravenously over 20 minutes on days 1 and 8, and elimusertib orally once daily on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles as long as there is no disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up to 30 days, then every 3 months thereafter.
Study Sites:
California
- Sacramento
University of California Davis Comprehensive Cancer Center
Contact Person: Dr. Mamta Parikh at 916-734-3089
Maryland
- Bethesda
National Cancer Institute Developmental Therapeutics Clinic
Contact Person: Dr. Naoko Takebe at 800-411-1222
New York
- New York
NYP/ Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Contact Person: Dr. Mark Stein at [email protected]
Ohio
- Columbus
Ohio State University Comprehensive Cancer Center
Contact Person: Dr. Ming Yin at [email protected] or 800-293-5066
Pennsylvania
- Pittsburgh
University of Pittsburgh Cancer Institute
Contact Person: Dr. Leonard Appleman at 412-647-8073
Wisconsin
- Madison
University of Wisconsin Carbone Cancer Center
Contact Person: Dr. Hamid Emamekhoo at 800-622-8922
Ontario, Canada
- Toronto
University Health Network-Princess Margaret Hospital
Contact 416-946-4501 or [email protected]
This Study is Open To:
This study is no longer enrolling people.
This Study is Not Open To:
This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.